Lucas Kohorst
@lucas
days @dcgco nights @adjacent___
Lucas Kohorst
@lucas
days @dcgco nights @adjacent___
The text analyzes Cassava Sciences' simufilam, predicting its failure in Phase 3 trials for Alzheimer's disease due to ineffective mechanisms, poor pharmacokinetics, and manipulative data practices.
ontheimpossible.vercel.app